Innovations in Oncology: The Science of Trilaciclib

September 15, 2022
Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this presentation include, but are not limited to, those relating to expectations for COSELA® to impact survival, COSELA’s ability to impact the future of standard of care, COSELA’s dual benefits efficacy, and COSELA’s preclinical data may not be indicative of results in clinical trials. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause our actual results to differ from those expressed or implied in the forward-looking statements in this presentation are discussed in our filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, our ability to continue to commercialize COSELA (trilaciclib); our ability to complete clinical trials for, obtain approvals for and commercialize additional indications of COSELA; our initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a commercial-stage company; and market conditions. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

G1Therapeutics™ and G1Therapeutics logo and COSELA® and COSELA logo are trademarks of G1 Therapeutics, Inc. ©2022 G1 Therapeutics, Inc.
Agenda

Welcome and Agenda
Will Roberts, Vice President, Investor Relations & Corporate Communications

Introduction to G1 Therapeutics
Jack Bailey, Chief Executive Officer

Trilaciclib: From Premise to Promise
Raj Malik, M.D., Chief Medical Officer

Trilaciclib (transient CDK4/6/i) as Immunomodulatory Therapy for Cancer
Shom Goel, B Med Sci, MBBS, FRACP, Ph.D., Peter MacCallum Cancer Centre, The University of Melbourne

The Synergistic Potential of Trilaciclib
John Yi, Ph.D., Sr. Director, Translational Medicine

Clinical Development: Expanding the Trilaciclib Opportunity
Symantha Melemed, Ph.D., Vice President, Clinical Development

Moderated Discussion: The Colorectal Cancer Treatment Landscape
Richard Goldberg, M.D., Professor Emeritus and former Director, West Virginia University Cancer Institute (WVUCI)
Moderator: Norm Nagl, Ph.D., Vice President, Medical Affairs

Trilaciclib Market Opportunity and Future Focus
Mark Avagliano, Chief Business Officer

Concluding Remarks and Transition to Q&A
Jack Bailey, Chief Executive Officer

Q&A with G1 Leadership
Introduction to G1 Therapeutics

Jack Bailey, Chief Executive Officer
G1 and Trilaciclib
Leading Research into Cell Cycle Modulation since 2008

2008-2012
G1 founded by Ned Sharpless & Kwok-Kin Wong: Modulate the cell-cycle to protect the bone marrow from damage by chemotherapy

2008-2012
- Immune analysis of Phase 2 data shows enhanced immune function (SITC)
- Trilaciclib demonstrates improvement in OS in TNBC (*Lancet Oncology*)
- Trilaciclib demonstrates myeloprotection in three SCLC studies
- Breakthrough Therapy designation for trilaciclib in SCLC
- Trilaciclib NDA accepted in U.S.
- Priority review granted by U.S. FDA
- Enrollment complete in Phase 2 MOA and bladder cancer trials

2013
- G1T28 (trilaciclib) selected as IV CDK4/6i candidate

2014
- Trilaciclib IND filed
- Initiated Phase 1 study for trilaciclib

2015
- Initiated Phase 2 clinical program for trilaciclib in ES-SCLC

2016
- Initiated Phase 2 clinical program for trilaciclib in TNBC

2017
- Trilaciclib demonstrates myeloprotection in three SCLC studies

2018
- Breakthrough Therapy designation for trilaciclib in SCLC

2019
- Trilaciclib NDA accepted in U.S.
- Priority review granted by U.S. FDA

2020
- Trilaciclib approved for ES-SCLC and launched

2021
- Enrollment complete in Phase 3 CRC trial

2022
- Enrollment complete in Phase 2 MOA and bladder cancer trials
Currently Pursuing Trilaciclib Across Key Growth Platforms

**Myeloprotection:**
Protecting the bone marrow from cytotoxic damage

**Immunomodulation:**
Improving overall immune response

**Reduction in Hematologic Adverse Events**

**Improved Survival**

**Future Indications**

**Survival in combination with leading and emerging treatments**¹

¹ Clinical evaluation underway; the safety and efficacy of an investigational use of an approved product have not been established or approved by the FDA or other regulatory authorities.
Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch

1. COSELA is marketed in the U.S. by G1 and conditionally approved in Greater China to be marketed by our partner, Simcere.
2. 1L CRC data readout in 1Q 2023 expected to include results for myeloprotection and Objective Response Rate (ORR) endpoints.
3. 1L TNBC data readout in 2H 2023 expected to include interim results for Overall Survival (OS); interim OS analysis to be conducted by its DMC in 2H 2023.
4. 2L / 3L TNBC (in combination with an ADC) initial data in 4Q 2022 expected to include ORR and myeloprotection endpoints.
5. 1L Bladder Cancer (in combination with an anti-PD-L1) initial data in 4Q 2022 expected to include ORR and myeloprotection endpoints.
6. MOA in Neoadjuvant TNBC +/- PD-1 inhibitor (investigator discretion); data readout in 4Q 2022 to include Results for immune endpoints; data readout in 1H 2023 to include pCR.
Takeaways for Today

- Trilaciclib’s unique effects attributable to transient, potent, and selective CDK4/6 inhibition and directly targeting the host
- Trilaciclib enhances multiple immunological processes within the cancer immunity cycle
- Potential for improved survival via improved immune response (immunomodulation) and increased cytotoxic exposure while protecting immune system (myeloprotection)
- New preclinical data show consistent synergistic potential
- Meaningful data read-outs starting in the next three months and continuing through 2023
- Trilaciclib represents a pipeline-in-a-molecule opportunity with significant expansion opportunities in future standard of care
Trilaciclib: From Premise to Promise

Raj Malik, M.D., Chief Medical Officer
Evolution of G1 and Exciting Road Ahead

Original Premise

To protect HSPCs from damage caused by chemo through transient G1 arrest

Unique Product

Rationally designed and optimized a unique IV transient CDK4/6 inhibitor

Initial Indication

Demonstrated robust myeloprotection across three Phase 2 ES-SCLC studies

Robust OS in TNBC

OS hazard ratios in Ph2: 0.31 – 0.40

Dual Benefits

Potential to improve overall survival through:

1. Increased cytotoxic exposure
2. Enhanced anti-tumor immunity

Aggressively investigating dual benefit impact across multiple tumor types

Multiple clinical studies ongoing to demonstrate the dual benefits of trilaciclib and the potential to improve overall survival
Effects of Trilaciclib Directly Target the “Host”
Patient Bone Marrow and Tumor Immune Microenvironment

Trilaciclib’s robust effects on bone marrow and immune system function occur through the distinct properties of trilaciclib

Trilaciclib’s robust effects on bone marrow and immune system function occur through the distinct properties of trilaciclib
Host Effects Driven by Transient CDK4/6 Inhibition

Helps protect HSPCs and myeloid and lymphoid cell lineages from damage caused by cytotoxic therapy1-3

Reduces Hematologic Adverse Events

- Neutrophils
- Erythrocytes
- Platelets
- T-lymphocytes
- B-lymphocytes

Improves patients’ quality of life
Decreases rescue interventions, hospitalizations, associated costs
Protects immune system function from damage by cytotoxic therapy
Enables patients to tolerate greater exposure to cytotoxic therapy

Ability to improve the immune response when administered in treatment combination4-11

Improves Anti-Tumor Immune Response

- MHC-I & II
- IL-2 / IFNγ secretion
- Th1 cytokines
- Treg / MDSCs
- Memory T cells

Enhances T cell activation
Favorably alters the tumor microenvironment
Improves long-term immune surveillance

Unique Attributes of Trilaciclib

<table>
<thead>
<tr>
<th>Trilaciclib’s Attributes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid onset from IV administration</td>
</tr>
<tr>
<td>Potent and selective CDK4 and CDK6 inhibition</td>
</tr>
<tr>
<td>Short half-life</td>
</tr>
</tbody>
</table>

- Controlled administration and clean G1 arrest reduces hematologic AEs caused by chemotherapy and may increase ability to receive longer treatment durations.
- Transient CDK4/6 inhibition modulates multiple immune functions while also allowing beneficial T cell proliferation which may improve patients’ anti-tumor immune response.

The profile of trilaciclib drives robust patient benefits of myeloprotection and/or potential to increase anti-tumor immunity.
Meaningful Reduction in Adverse Events in ES-SCLC Phase 2: Randomized Studies

Reduced Incidence of Multi-lineage Myelosuppression in 1L SCLC Treated with trilaciclib and Etoposide/Carboplatin/Atezolizumab

Reduced Grade 3/4 Hematological Adverse Reactions Occurring in Patients Treated with trilaciclib and Placebo

Trilaciclib demonstrated reductions in multiple myelosuppressive consequences and hematologic adverse events across multiple randomized SCLC studies

1. COSELA® (trilaciclib) label, 10003 Rev. 2/2021 US-2100006
2. Weiss et al., 2020 American Society of Clinical Oncology (ASCO), Abstract #384
Observed Robust OS Improvement in mTNBC Study
Phase 2: Combination with Chemotherapy

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Median OS, months</th>
<th>Hazard Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1: (gem/carbo)</td>
<td>12.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Group 2: (gem/carbo + trilaciclib)</td>
<td>Not Reached</td>
<td>0.31 (0.15-0.63)</td>
<td>0.0016</td>
</tr>
<tr>
<td>Group 3: (gem/carbo + trilaciclib)</td>
<td>17.8</td>
<td>0.40 (0.22-0.74)</td>
<td>0.0004</td>
</tr>
</tbody>
</table>

OS continued to improve over time and at greater rate than PFS for trilaciclib, consistent with a robust immunomodulatory effect

1. O’Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06. Note: primary endpoints relating to reduction in severe neutropenia not achieved in this study.
2. Patients randomized to receive gem/carbo chemotherapy only (Group 1) or gem/carbo plus one of two dosing schedules of COSELA: COSELA administered on the day of chemotherapy (Group 2) or COSELA administered the day prior to and the day of chemotherapy (Group 3).
Overall Survival Most Significant Effect in mTNBC Study
Phase 2: Combination with Chemotherapy

1. O’Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06. Note: primary endpoints relating to reduction in severe neutropenia not achieved in this study.

2. Patients randomized to receive gem/carbo chemotherapy only (Group 1) or gem/carbo plus one of two dosing schedules of trilaciclib: trilaciclib administered on the day of chemotherapy (Group 2) or trilaciclib administered the day prior to and the day of chemotherapy (Group 3).

Trilaciclib demonstrated the most robust effect on OS, consistent with its observed immunomodulatory effects.
Currently Pursuing Trilaciclib Across Key Growth Platforms

- **Myeloprotection:** Protecting the bone marrow from cytotoxic damage
  - Reduction in Hematologic Adverse Events
  - ES-SCLC

- **Myeloprotection:** Enabling increased cytotoxic exposure while protecting immune system
  - Improved Survival

- **Immunomodulation:** Improving overall immune response
  - Improved Survival

**Survival in combination with leading and emerging treatments**

---

1 Clinical evaluation underway; the safety and efficacy of an investigational use of an approved product have not been established or approved by the FDA or other regulatory authorities.
### Trilaciclib’s Effects Depend on Treatment Setting and Tumor Type

<table>
<thead>
<tr>
<th>Evidence for myeloprotection with cytotoxic / payload</th>
<th>Extended cycles of therapy</th>
<th>Known immunogenic tumor</th>
<th>Combination with immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1L Colorectal Cancer (Phase 3: +FOLFOXIRI)</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>2L / 3L TNBC (Phase 2: +Sacituzumab)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>1L TNBC (Phase 3: +Gem/Carbo)</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>1L Bladder Cancer (Phase 2: +Gem/Platinum and avelumab maintenance)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Neoadjuvant TNBC (Phase 2: ACT +/- PD-(L)1i)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>ES-SCLC (Marketed)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

- Myeloprotection benefits; no increase in OS demonstrated

* One of the three ES-SCLC trials included atezolizumab in the treatment regimen; however, trilaciclib was not dosed with atezolizumab for maintenance portion of study.

**Myeloprotection**: Protecting the bone marrow from cytotoxic damage

**Myeloprotection**: Enabling increased cytotoxic exposure while protecting immune system

**Immunomodulation**: Improving overall immune response
Key Takeaways: From Premise to Promise

- Trilaciclib’s unique effects are directly targeted on the host
- Robust effects attributable to unique transient, potent, and selective CDK4/6 inhibition
- Protection of patient’s bone marrow leads to multilineage myeloprotection benefits
- Improved immune system function and myeloprotection anticipated to lead to anti-tumor efficacy
- In ongoing trials, most robust anti-tumor efficacy effect expected on survival, with least impact on response rate
- Meaningful data read-outs starting in the next three months
Trilaciclib as immunomodulatory therapy for cancer

Shom Goel B Med Sci, MBBS, FRACP, PhD
Peter MacCallum Cancer Centre
The University of Melbourne
Sustained proliferation: a hallmark of cancer

Certain cancer cells are heavily dependent on **CDKs 4 and 6** for proliferation and/or survival

3 agents approved as therapy for luminal breast cancer
CDK4/6 inhibition: Beyond cell cycle arrest

Goel et al
Nature Reviews Cancer
2022
CDK4/6 inhibition triggers anti-tumour immunity

Shom Goel¹,²*, Molly J. DeCristo³,⁴*, April C. Watt¹, Haley BrinJones¹, Jaclyn Sceneay³,⁴, Ben B. Li¹, Naveed Khan¹, Jessalyn M. Ubellacker³,⁴, Shaozhen Xie¹, Otto Metzger–Filho², Jeremy Hoog⁵, Matthew J. Ellis⁶, Cynthia X. Ma⁵, Susanne Ramm⁷,⁸, Ian E. Krop², Eric P. Winer², Thomas M. Roberts¹, Hye-Jung Kim⁹,¹⁰§, Sandra S. McAllister³,⁴,¹¹,¹²§ & Jean J. Zhao¹,¹²,¹³§
CDK4/6 inhibitor-induced anti-tumor immunity - Clues from the past -

TCR Antigen–Induced Cell Death Occurs from a Late G1 Phase Cell Cycle Check Point

Howard Hughes Medical Institute and Division of Molecular Oncology
Departments of Pathology and Medicine
Washington University School of Medicine
St. Louis, Missouri 63110

Immunity 1998

A common E2F-1 and p73 pathway mediates cell death induced by TCR activation

Natalie A. Lissy, Penny K. Davis, Meredith Irwin, William G. Kaelin, & Steven F. Dowdy

Nature 2000

Regulation of T Cell Differentiation and Alloimmunity by the Cyclin-Dependent Kinase Inhibitor p18ink4c

Emily A. Rowell, Liqing Wang, Neelanjana Chunder, Wayne W. Hancock, Andrew D. Wells

PLOS One 2014
CDK4/6 inhibitor-induced anti-tumor immunity
- Confirmation of mechanism -

Tumor cell antigen presentation
• Goel *Nature* 2017
• Schaer *Cell Rep* 2018
• Stopfer *Nat Comm* 2020
• Knudsen *Gut* 2020
• Charles *Oncoimmunology* 2021
• Watt *Nature Cancer* 2021
• Wu *J Trans Med* 2022

Tumor cell chemokine secretion
• Ruscetti *Science* 2018
• Uzhachenko *Cell Rep* 2021

Suppression of Treg proliferation
• Goel *Nature* 2017
• Lai *JITC* 2020
• Whittle *Clin Cancer Res* 2020
• Uzhachenko *Cell Rep* 2021

Generation of immune memory
• Goel *Nature* 2017
• Lelliott *Cancer Discovery* 2021
• Heckler *Cancer Discovery* 2021

Effector T cell activation
• Deng *Cancer Discovery* 2018

Combination with checkpoint inhibitors
• Goel *Nature* 2017
• Zhang *Nature* 2018
• Schaer *Cell Rep* 2018
• Jerby-Aronon *Cell* 2018
• Deng *Cancer Discovery* 2018
• Knudsen *Gut* 2020
• Lai *JITC* 2020
• Uzhachenko *Cell Rep* 2021
Trilaciclib: uniquely poised to exploit the immunomodulatory properties of CDK4/6 inhibitors

Intravenous administration enables potentiation of anti-tumor immunity:
• Precision with intermittent dosing
• Temporal control of T cell transcriptome
• Balancing T cell function and number
• Easy integration with existing standards of care

Potential for combination with chemotherapy, immunotherapy, or both across a wide range of cancer types
The Synergistic Potential of Trilaciclib

John Yi, Ph.D., Sr. Director, Translational Medicine
Potential to Enhance the Cancer Immunity Cycle
Ideal for Combination Use

1. Release of Cancer Cell Antigens
2. Cancer Antigen Presentation
3. Priming and Activation
4. Trafficking of T cells to Tumors
5. Infiltration of T cells into Tumors
6. Recognition of Cancer Cells by T Cells
7. Killing of Cancer Cells


Potential to Enhance the Cancer Immunity Cycle
Ideal for Combination Use

1. Release of Cancer Cell Antigens
   - RTK Inhibitors
   - STING Agonist
   - CD47 Blockade

2. Cancer Antigen Presentation
   - IL-2
   - CTLA-4 Blockade
   - A2aR/CD73 Blockade

3. Priming and Activation
   - PD-(L)1/TIGIT/LAG-3/TIM-3 Blockade
   - NKG2A Blockade

4. Trafficking of T cells to Tumors
   - Anti-VEGF
   - CAR-T
   - BITE

5. Infiltration of T cells into Tumors
   - CDK4/6 Blockade

6. Recognition of Cancer Cells by T Cells
   - CD47 Blockade
   - STING Agonist

7. Killing of Cancer Cells
   - PD-(L)1/TIGIT/LAG-3/TIM-3 Blockade
   - NKG2A Blockade


Potential to Enhance the Cancer Immunity Cycle
Ideal for Combination Use

1. Release of Cancer Cell Antigens
2. Cancer Antigen Presentation
3. Priming and Activation
4. Trafficking of T cells to Tumors
5. Infiltration of T cells into Tumors
6. Recognition of Cancer Cells by T Cells
7. Killing of Cancer Cells


Gene Expression Changes Within Tumor Infiltrating T Cells

**Note:** In a MMTV-rtTA/tetO-HER2 model of breast cancer, mice were treated with a single dose of trilaciclib. Single cell RNA-Seq performed on sorted tumor-derived CD3+ T cells 24 hours after treatment.

* Gene expression changes with trilaciclib potentiates the broad immune modulating effect

* Work conducted in collaboration with Dr. Shom Goel (Peter MacCallum Institute)
Enhanced Potential for Antigen Presentation and T Cell Activation

Upregulation of MHC and PD-L1
(on MCF-7 Cell Line)

**Note:** MCF-7 breast cancer cell line were cultured with supernatant from stimulated PBMCs (+/- trilaciclib; 100nM).

Enhanced T Cell Activation
(trilaciclib + oxaliplatin + anti-PD-L1)

**Note:** Splenocytes were analyzed 5 days after treatment in a MC38 model

Favorable Alteration of the Tumor Microenvironment

Increased Chemokines & Cytokines\(^1\)

- IL16
- IFNγ
- CXCL9
- CXCL16
- CXCL10

Note: Multiplex immunoassay performed on patient-derived organoid cultures

Prolonged Arrest of Treg Proliferation\(^2\)
(trilaciclib + oxaliplatin + anti-PD-L1)

<table>
<thead>
<tr>
<th>Schedule*</th>
<th>Trila</th>
<th>Oxaliplatin</th>
<th>Anti-PD-L1</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>↑</td>
<td>↑</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>↑</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Relative proliferation is defined as the proportion of EdU+ cells in vehicle-treated samples

Suppression of Treg Function \(^1\)

- CD8+ T-cell proliferation
- Relative proliferation (%)

Note: Tregs were pretreated with trilaciclib prior to Treg suppression assay.

Improvement of Long-Term Immune Surveillance

Expression of Memory-Associated Genes

- **Sell**: ****
- **IL7r**: ****
- **Tcf7**: ****

<table>
<thead>
<tr>
<th>Expression level</th>
<th>Vehicle</th>
<th>CDK4/6i (trilaciclib)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note**: Expression of Memory-associated genes at day 7 following trilaciclib treatment.

Preferential Differentiation into Memory CD8 T Cells

- **Intra-tumor CD8+ T subsets**
  - Naive
  - TEM
  - TCM
  - TEFF

**Comparison of frequency of intra-tumor T cell subsets between OP and TOP groups**

- Naive CD8+:
  - OP: 1.2 ± 0.6
  - TOP: 1 ± 0.4
  - P-value: 0.81

- CD8+ TEFF:
  - OP: 21.8 ± 2.5
  - TOP: 11.3 ± 1.4
  - P-value: 0.01

- CD8+ TCM:
  - OP: 75.6 ± 2.3
  - TOP: 86.2 ± 1.6
  - P-value: 0.01

- CD8+ TEM:
  - OP: 15 ± 0.8
  - TOP: 15 ± 0.4
  - P-value: 0.97

**Note**: CD8+ T cells were divided into four subsets using CD62L and CD44 markers: naïve T cells (CD62L+CD44-), effector (TEFF,CD62L+CD44+), central memory (TCM, CD62L+CD44+), and effector memory (TEM, CD62L-CD44+).

Synergistic Anti-Tumor Activity with PD-(L)1 Inhibitors and Chemotherapy

Trilaciclib Combined with a PD-1 inhibitor\(^1\)

![Graph showing the effect of Trilaciclib combined with a PD-1 inhibitor on tumor volume and L2(%) and IFN(%) over different days.](image)

**Note:** Cytokines were evaluated on Day 17

Trilaciclib Combined with a PD-(L)1 + Chemo\(^1\)

![Graph showing the effect of Trilaciclib combined with a PD-(L)1 + Chemotherapy on tumor growth and survival.](image)

Efficacy of Combination Therapy with Inhibitory Receptors

Trilaciclib + Dual Checkpoint Blockade (CT26 Model)

Trilaciclib supports therapies inhibiting both checkpoint and adenosine pathways
Key Takeaways: The Synergistic Potential of Trilaciclib

- Trilaciclib has the potential to enhance multiple immunological processes within the cancer immunity cycle \(^1\)
  - Enhances T cell activation
  - Favorably alters the tumor microenvironment
  - Improves long-term immune surveillance
- Trilaciclib provides synergistic benefit in combination with checkpoint and adenosine pathway inhibition
  - Added survival benefit when combined with PD-1 and LAG3 or CD73 inhibitors
- Ongoing Phase 2 TNBC MOA study will confirm and expand trilaciclib’s benefit in additional combination therapy opportunities
Clinical Development: Expanding the Trilaciclib Opportunity

Symantha Meledem, Ph.D., Vice President, Clinical Development
Trilaciclib’s Effects Depend on Treatment Setting and Tumor Type

<table>
<thead>
<tr>
<th>Evidence for myeloprotection with cytotoxic / payload</th>
<th>Extended cycles of therapy</th>
<th>Known immunogenic tumor</th>
<th>Combination with immunotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1L Colorectal Cancer</strong>&lt;br&gt;(Phase 3: +FOLFOXIRI)</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td><strong>2L / 3L TNBC</strong>&lt;br&gt;(Phase 2: +Sacituzumab)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>1L TNBC</strong>&lt;br&gt;(Phase 3: +Gem/Carbo)</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td><strong>1L Bladder Cancer</strong>&lt;br&gt;(Phase 2: +Gem/Platinum and avelumab maintenance)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>Neoadjuvant TNBC</strong>&lt;br&gt;(Phase 2: ACT +/- PD-(L)1i)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td><strong>ES-SCLC</strong>&lt;br&gt;(Marketed)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

Myeloprotection benefits; no increase in OS demonstrated

Myeloprotection: Protecting the bone marrow from cytotoxic damage

Myeloprotection: Enabling increased cytotoxic exposure while protecting immune system

Immunomodulation: Improving overall immune response

* One of the three ES-SCLC trials included atezolizumab in the treatment regimen; however, trilaciclib was not dosed with atezolizumab for maintenance portion of study.
Ongoing Pivotal Phase 3 Studies
First-Line CRC Benchmark Data (from a meta-analysis\(^1\))  
Foundational Data for PRESERVE 1: Triplet Efficacious but Highly Myelosuppressive

<table>
<thead>
<tr>
<th></th>
<th>FOLFOXIRI + bevacizumab (N = 846)</th>
<th>Doublet + bevacizumab (N = 851)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy Data:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ORR</td>
<td>64.5%</td>
<td>53.6%</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Median PFS</td>
<td>12.2</td>
<td>9.9</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Median OS</td>
<td>28.9</td>
<td>24.5</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Most Common Adverse Events:</strong> (Grade 3 - 4 AEs occurring &gt; 5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutropenia(^2)</td>
<td>45.8%</td>
<td>21.5%</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>17.8%</td>
<td>8.4%</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Arterial Hypertension</td>
<td>7.8%</td>
<td>7.8%</td>
<td>.938</td>
</tr>
<tr>
<td>Febrile Neutropenia</td>
<td>6.3%</td>
<td>3.7%</td>
<td>.019</td>
</tr>
<tr>
<td>Nausea</td>
<td>5.5%</td>
<td>3.0%</td>
<td>.016</td>
</tr>
<tr>
<td>Venous Thromboembolism</td>
<td>5.5%</td>
<td>5.7%</td>
<td>.892</td>
</tr>
<tr>
<td>Mucositis</td>
<td>5.1%</td>
<td>2.9%</td>
<td>.024</td>
</tr>
</tbody>
</table>

---


2. Note: Grade 4 neutropenia ~19% for FOLFOXIRI + bevacizumab and ~7% for doublet + bevacizumab based on TRIBE2 results (Cremolini, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020; 21: 497–507.)
Ongoing P3 First-Line CRC Pivotal Trial: PRESERVE 1

Myeloprotection & Extended Cycles

FOLFOXIRI: most efficacious chemo regimen but highly myelosuppressive
Potential to significantly expand FOLFOXIRI usage supported by market research

**PRIMARY ENDPOINT:**
Myeloprotection
SN during Induction & DSN Cycles 1-4
Powering unchanged

**SECONDARY ENDPOINTS:**
PFS/OS, PRO

**ENROLLMENT COMPLETED:**
326 participants

**STATISTICS:**
Myelo + PRO: $\alpha = 0.04$
PFS/OS: $\alpha = 0.01$

*Initial results in 1Q 2023*

Strong support from preclinical models for the benefits of trilaciclib in combination with 5-FU-based chemo regimens
Observed Robust OS Improvement in mTNBC
Completed Phase 2: Foundational Data for PRESERVE 2

Overall Survival in Intent-to-Treat Population¹

<table>
<thead>
<tr>
<th>Treatment Group²</th>
<th>Median OS, months</th>
<th>Hazard Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1: (gem/carbo)</td>
<td>12.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Group 2: (gem/carbo + trilaciclib)</td>
<td>Not Reached</td>
<td>0.31 (0.15-0.63)</td>
<td>0.0016</td>
</tr>
<tr>
<td>Group 3: (gem/carbo + trilaciclib)</td>
<td>17.8</td>
<td>0.40 (0.22-0.74)</td>
<td>0.0004</td>
</tr>
</tbody>
</table>

Fast Track Designation granted as a result of these data (July 2021)

¹. O'Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #PD1-06. Note: primary endpoints relating to reduction in severe neutropenia not achieved in this study.
2. Patients randomized to receive gem/carbo chemotherapy only (Group 1) or gem/carbo plus one of two dosing schedules of COSELA: COSELA administered on the day of chemotherapy (Group 2) or COSELA administered the day prior to and the day of chemotherapy (Group 3).
Ongoing First-Line TNBC P3 Pivotal Trial: PRESERVE 2
Extended Cycles & Immunogenic Tumor

Initital positive evidence of efficacy across subsets and line of treatment in Phase 2 trial\(^1\)
Evaluating 1L patients (PD-L1 positive and negative patients)

Cohort 1: 1L TNBC (checkpoint naive)

<table>
<thead>
<tr>
<th>Randomization 1:1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Placebo + gem/carbo on Days 1 and 8 every 21 days until progression</td>
</tr>
<tr>
<td>trilaciclib + gem/carbo on Days 1 and 8 every 21 days until progression</td>
</tr>
</tbody>
</table>

**PRIMARY ENDPOINT:**
Overall Survival

**SECONDARY ENDPOINTS:**
PRO, myeloprotection measures, PFS/ORR

**TARGET ENROLLMENT:**
~180 1L participants

Interim OS analysis at 70% of events in 2H 2023

Pivotal study evaluating trilaciclib in mTNBC building upon robust OS benefit observed in prior Phase 2 study

---

\(^1\) O'Shaughnessy et al., 2020 San Antonio Breast Cancer Symposium (SABCS), Poster #P1-06
Ongoing Phase 2 Studies
Three Near-Term Phase 2 Proof of Concept Readouts

**Proof of Concept Study**

**2L / 3L TNBC (Phase 2)**

1. Demonstrate ability to increase survival across additional tumors (i.e., beyond mTNBC)

2. Evaluate if synergistic benefits with a CPI observed preclinically is translatable to humans

**Key Goals of Study Related to Trilaciclib**

1. Evaluate myeloprotection benefits with an ADC (sacituzumab govitecan in this study)
2. Determine whether increased cytotoxic exposure and potential synergy increases PFS / OS

**1L Bladder Cancer (Phase 2)**

1. Demonstrate ability to increase survival across additional tumors (i.e., beyond mTNBC)
2. Evaluate if synergistic benefits with a CPI observed preclinically is translatable to humans

**Neoadjuvant TNBC (Phase 2)**

1. Clinically confirm mechanistic effects that appear to be driving increased immunomodulation
2. Evaluate if there is an anti-tumor efficacy signal in early stage TNBC patients
Evaluate synergistic combo potential of trilaciclib and sacitizumab govitecan-hziy, each of which have individually demonstrated clinically meaningful OS improvements in TNBC

**Primary Endpoint:** PFS

**Secondary Endpoints:** ORR, CBR, OS, myeloprotection measures

**Target Enrollment:** ~40 participants

**Patients Treated Until Progression**

*Initial results in 4Q 2022*

*Strong belief in clinical rationale underlying this combo; data generated will be instructive in evaluating future ADC combo possibilities.*
Phase 2 Bladder (mUC) Study: PRESERVE 3
Extended Cycles, Immunogenic Tumor & Combination with Immunotherapy

Building on strong rationale for trilaciclib + chemo + checkpoint inhibitor; data to date suggest potential for synergistic effect in known immunogenic tumor

**Treatment Phase**

**Induction Phase**

- Cycle X Day 1: platinum-based chemotherapy
- Cycle X Day 8: platinum-based chemotherapy
- Cycle X Day 21: trilaciclib + platinum-based chemotherapy

**Maintenance Phase**

- Cycle X Day 1: avelumab
- Cycle X Day 21: trilaciclib + avelumab

**Primary Endpoint:** PFS

**Secondary Endpoints:** ORR, DCR, DOR, OS, myeloprotection measures

**Enrollment Completed:** 92 participants

**Patients Treated Until Progression**

Initial results in 4Q 2022

Phase 2 study will provide meaningful data for trilaciclib in a known immunogenic setting; expected to help define future combination studies
Phase 2 Neoadjuvant TNBC: Mechanism of Action (MOA) Study
Extended Cycles, Immunogenic Tumor & Combination with Immunotherapy

Confirm immune-based properties of trilaciclib and its potential role in increasing the anti-tumor efficacy of chemotherapy with and without a checkpoint inhibitor

**Primary Endpoint:**
Immune-based MOA

**Secondary Endpoints:**
pCR, immune response and profiling measures

**Enrollment Completed:**
24 patients

Initial results in 4Q 2022

Data generated from MOA study will inform design of future additional pivotal studies across multiple tumor types and treatment combinations
Key Takeaways: Expanding the Trilaciclib Opportunity

- Robust portfolio of ongoing Phase 2 and Phase 3 studies
- Phase 3 label expansion opportunities in CRC and TNBC
  
  Initial results available in 2023  →  Registration

- Phase 2 trials providing proof of concept for trilaciclib in multiple treatment combinations with drug classes expected to be foundational in future standards of care
  
  Initial results available in 2022  →  Pivotal Studies
Moderated Discussion: The Colorectal Cancer Treatment Landscape

Richard Goldberg, M.D., Professor Emeritus and former Director, West Virginia University Cancer Institute (WVUCI)
Moderator: Norm Nagl, Ph.D., Vice President, Medical Affairs
Trilaciclib Market Opportunity and Future Focus

Mark Avagliano, Chief Business Officer
Currently Focused on Common Tumor Types

U.S. Annual Incidence and Deaths\(^1\)

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Estimated New Cases</th>
<th>Estimated Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorectal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bladder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

G1 Development and Commercialization

<table>
<thead>
<tr>
<th>POC</th>
<th>Pivotal</th>
<th>Marketed</th>
</tr>
</thead>
<tbody>
<tr>
<td>2L/3L TNBC</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Neo(adj) TNBC</td>
<td>✔️</td>
<td></td>
</tr>
<tr>
<td>1L NSCLC</td>
<td>✔️</td>
<td></td>
</tr>
<tr>
<td>1L CRC</td>
<td>✔️</td>
<td></td>
</tr>
<tr>
<td>1L Bladder</td>
<td>✔️</td>
<td></td>
</tr>
</tbody>
</table>

1. Estimated new cases and deaths from National Cancer Institute for 2022 for the six most common tumor types (ranked by annual incidence).
1L CRC: Meaningful Near-Term Potential Opportunity

Chemotherapy remains primary backbone for mCRC
- Majority of patients have microsatellite stable (MSS) tumors
- ~47k annual first-line drug-treated MSS CRC patients in the U.S

FOLFOXIRI only used in ~10% to ~20% of U.S. patients
- Most efficacious regimen but currently limited due to toxicities
- Typically reserved for younger healthier patients with larger tumors

Significant potential to expand FOLFOXIRI usage
- Meaningfully reduced myelosuppression addresses critical hurdle
- Patients receive 4 vials of trilaciclib for each 2-week cycle

Meaningfully reducing the myelosuppression associated with FOLFOXIRI expected to enable broader use across 1L MSS CRC patients

1. Estimates from secondary data, and internal analysis and primary research
1L TNBC: Important Area of High Unmet Need

Meaningfully increasing overall survival broadly across 1L TNBC subpopulations addresses a high unmet need area (particularly without increasing toxicity)

U.S. TNBC Patient Population (2021)¹

- TNBC tumors are aggressive and difficult to treat
  - Categorized by lack of HR expression and HER2 gene amplification
  - Trilaciclib demonstrated robust survival benefit with chemo in Ph2

- Chemo +/- targeted therapy remains first-line TNBC SoC
  - ~9k annual first-line drug treated TNBC patients in the U.S.
  - Targeted therapies only demonstrated benefit in subpopulations

- Trilaciclib demonstrated broad benefit in Phase 2
  - Benefit observed across PD-(L)1+ and PD-(L)1- subpopulations
  - Patients receive 4 vials of trilaciclib for each 3-week cycle

¹. Estimates from secondary data, and internal analysis and primary research
### Three Near-Term Phase 2 Proof of Concept Readouts

#### Key Goals of Study Related to Trilaciclib

<table>
<thead>
<tr>
<th>Proof of Concept Study</th>
<th>1. Demonstrate ability to increase survival across additional tumors (i.e., beyond mTNBC)</th>
<th>2. Evaluate if synergistic benefits with a CPI observed preclinically is translatable to humans</th>
</tr>
</thead>
<tbody>
<tr>
<td>2L / 3L TNBC (Phase 2)</td>
<td>1. Evaluate myeloprotection benefits with an ADC (sacituzumab govitecan in this study)</td>
<td>2. Determine whether increased cytotoxic exposure and potential synergy increases PFS / OS</td>
</tr>
<tr>
<td>1L Bladder Cancer (Phase 2)</td>
<td>1. Demonstrate ability to increase survival across additional tumors (i.e., beyond mTNBC)</td>
<td>2. Evaluate if synergistic benefits with a CPI observed preclinically is translatable to humans</td>
</tr>
<tr>
<td>Neoadjuvant TNBC (Phase 2)</td>
<td>1. Clinically confirm mechanistic effects that appear to be driving increased immunomodulation</td>
<td>2. Evaluate if there is an anti-tumor efficacy signal in early stage TNBC patients</td>
</tr>
</tbody>
</table>

These data will be important to confirm ability for trilaciclib to add meaningful benefit to patients in strategically important treatment settings.
# Potentially Ideal Treatment Settings for Future Studies

## Myeloprotection: Enabling increased cytotoxic exposure while protecting immune system

### ADCs
- (in areas ADC monotherapy may become SoC)

### ADC Combinations
- (in areas ADC combinations may become SoC)

### Other Highly Myelotoxic Regimens
- (e.g., FOLFIRINOX)

## Immunomodulation: Improving overall immune response

### CPI + Chemo/ADC
- (in immunogenic tumors)

### CPI Maintenance
- (metastatic or adjuvant uses)

### Future CPI Combos
- (e.g., PD-(L)1i + anti-LAG3; PD-(L)1i + anti-CD73)

---

Focused on ideal treatment settings where trilaciclib has unique ability to further improve survival in combination with important leading and emerging treatments.
Near-Term Data to Guide Future Development Decisions

2H 2022

2L / 3L TNBC
Phase 2 – ORR / Myelo.
(TROP2 ADC)

1L CRC
Phase 3 – Myelo.
(5-FU Based Regimen)

1L Bladder Cancer
Phase 2 - ORR
(CPI Maintenance)

Neoadjuvant TNBC
Phase 2 - pCR
(Early BC CPI Combination1)

1L TNBC
Phase 3 – Interim OS

1L CRC
Phase 3 – PFS/OS

Initiation of additional Phase 2 and Phase 3 studies

Initiation of additional Phase 2 and Phase 3 studies

Ongoing Preclin. Data
(emerging future combos)

2H 2022

1H 2023

2H 2023

2024

2025

1. Investigator discretion on whether to use CPI in study.

Myeloprotection: Enabling increased cytotoxic exposure while protecting immune system

Immunomodulation: Improving overall immune response
Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch

1. COSELA is marketed in the U.S. by G1 and conditionally approved in Greater China to be marketed by our partner, Simcere
2. 1L CRC data readout in 1Q 2023 expected to include results for myeloprotection and Objective Response Rate (ORR) endpoints
3. 1L TNBC data readout in 2H 2023 expected to include interim results for Overall Survival (OS); interim OS analysis to be conducted by its DMC in 2H 2023
4. 2L / 3L TNBC (in combination with an ADC) initial data in 4Q 2022 expected to include ORR and myeloprotection endpoints
5. 1L Bladder Cancer (in combination with an anti-PD-L1) initial data in 4Q 2022 expected to include ORR and myeloprotection endpoints
6. MOA in Neoadjuvant TNBC +/- PD-1 inhibitor (investigator discretion); data readout in 4Q 2022 to include results for immune endpoints; data readout in 1H 2023 to include pCR
Concluding Remarks and Transition to Q&A

Jack Bailey, Chief Executive Officer
Highlights from Today’s Event

- Trilaciclib’s unique effects attributable to transient, potent, and selective CDK4/6 inhibition and directly targeting the host
- Trilaciclib enhances multiple immunological processes within the cancer immunity cycle
- Potential for improved survival via improved immune response (immunomodulation) and increased cytotoxic exposure while protecting immune system (myeloprotection)
- New preclinical data show consistent synergistic potential
- Meaningful data read-outs starting in the next three months and continuing through 2023
- Trilaciclib represents a pipeline-in-a-molecule opportunity with significant expansion opportunities in future standard of care
Q&A with G1 Leadership
Innovations in Oncology:
The Science of Trilaciclib

September 15, 2022